PE20190351A1 - Agente terapeutico del sindrome de hunter y metodo de tratamiento - Google Patents
Agente terapeutico del sindrome de hunter y metodo de tratamientoInfo
- Publication number
- PE20190351A1 PE20190351A1 PE2017002893A PE2017002893A PE20190351A1 PE 20190351 A1 PE20190351 A1 PE 20190351A1 PE 2017002893 A PE2017002893 A PE 2017002893A PE 2017002893 A PE2017002893 A PE 2017002893A PE 20190351 A1 PE20190351 A1 PE 20190351A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- hunter
- treatment
- therapeutic agent
- syndrome therapeutic
- Prior art date
Links
- 201000002273 mucopolysaccharidosis II Diseases 0.000 title abstract 2
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 abstract 2
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere una formulacion para el tratamiento del sindrome de Hunter, la cual comprende una primera composicion para una inyeccion intravenosa y una segunda composicion para una inyeccion subcutanea. La primera composicion comprende iduronato 2-sulfatasa que consiste en por lo menos una de las secuencias de aminoacidos de las SEC ID Nos: 1 y 2, la cual se inyecta a una dosis efectiva de 0.05 mg/kg a 20 mg/kg por semana. La segunda composicion comprende iduronato 2-sulfatasa que consiste en por lo menos una de las secuencias de aminoacidos de las SEC ID Nos: 1 y 2, la cual se inyecta a una dosis efectiva de 0.1 mg/kg a 5 mg/kg por semana. La segunda composicion tambien comprende un tampon, un estabilizador y un potenciador de la absorcion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187867P | 2015-07-02 | 2015-07-02 | |
| KR1020150187297A KR20170004814A (ko) | 2015-07-02 | 2015-12-28 | 헌터증후군 치료제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190351A1 true PE20190351A1 (es) | 2019-03-07 |
Family
ID=57833331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002893A PE20190351A1 (es) | 2015-07-02 | 2016-07-04 | Agente terapeutico del sindrome de hunter y metodo de tratamiento |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10561713B2 (es) |
| EP (1) | EP3318267B1 (es) |
| JP (2) | JP6606199B2 (es) |
| KR (3) | KR20170004814A (es) |
| CN (1) | CN107921091A (es) |
| CA (1) | CA2990370C (es) |
| CL (1) | CL2018000002A1 (es) |
| CO (1) | CO2018000196A2 (es) |
| EA (1) | EA038110B1 (es) |
| ES (1) | ES2866957T3 (es) |
| HK (1) | HK1252663A1 (es) |
| MX (1) | MX379982B (es) |
| PE (1) | PE20190351A1 (es) |
| PL (1) | PL3318267T3 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY192762A (en) | 2015-07-02 | 2022-09-07 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| KR102671857B1 (ko) | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
| IL282120B1 (en) * | 2018-10-11 | 2025-04-01 | Indivior Uk Ltd | Buprenorphine for the treatment of respiratory depression |
| CA3106693A1 (en) * | 2019-02-06 | 2020-08-13 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type i |
| EP4166157A4 (en) | 2020-06-16 | 2024-03-06 | Novel Pharma Inc. | COMPOSITION FOR THE TREATMENT OF GLUTARIC ACIDURIA AND ASSOCIATED ADMINISTRATION METHOD |
| KR20250080887A (ko) * | 2022-12-29 | 2025-06-05 | 진동규 | 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010239861B2 (en) | 2009-04-22 | 2013-07-11 | Alteogen, Inc | In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP3875107A1 (en) * | 2010-06-25 | 2021-09-08 | Shire Human Genetic Therapies, Inc. | Pharmaceutical formulation comprising a replacement enzyme for a lysosomal enzyme for use in treating lysosomal storage disease intrathecally |
| ES2754234T3 (es) * | 2010-06-25 | 2020-04-16 | Shire Human Genetic Therapies | Métodos y composiciones para la administración SNC de iduronato-2-sulfatasa |
| KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| MX367395B (es) * | 2011-12-23 | 2019-08-20 | Shire Human Genetic Therapies | Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del síndrome de hunter mediante suministro intratecal. |
| EA201491578A1 (ru) * | 2012-03-30 | 2015-04-30 | Шир Хьюман Дженетик Терапис, Инк. | Подкожное введение идуронат-2-сульфатазы |
| JP2015013624A (ja) * | 2013-07-08 | 2015-01-22 | 船井電機株式会社 | 手動推進器具 |
-
2015
- 2015-12-28 KR KR1020150187297A patent/KR20170004814A/ko active Pending
-
2016
- 2016-07-04 US US15/738,017 patent/US10561713B2/en active Active
- 2016-07-04 EA EA201890182A patent/EA038110B1/ru unknown
- 2016-07-04 KR KR1020197036839A patent/KR102213055B1/ko active Active
- 2016-07-04 CA CA2990370A patent/CA2990370C/en active Active
- 2016-07-04 PE PE2017002893A patent/PE20190351A1/es unknown
- 2016-07-04 KR KR1020187001448A patent/KR20180015256A/ko not_active Ceased
- 2016-07-04 MX MX2017016302A patent/MX379982B/es unknown
- 2016-07-04 JP JP2017568199A patent/JP6606199B2/ja active Active
- 2016-07-04 PL PL16818303T patent/PL3318267T3/pl unknown
- 2016-07-04 ES ES16818303T patent/ES2866957T3/es active Active
- 2016-07-04 EP EP16818303.6A patent/EP3318267B1/en active Active
- 2016-07-04 HK HK18111970.1A patent/HK1252663A1/zh unknown
- 2016-07-04 CN CN201680038666.3A patent/CN107921091A/zh active Pending
-
2018
- 2018-01-02 CL CL2018000002A patent/CL2018000002A1/es unknown
- 2018-01-11 CO CONC2018/0000196A patent/CO2018000196A2/es unknown
-
2019
- 2019-09-05 JP JP2019161855A patent/JP6858231B2/ja active Active
- 2019-11-27 US US16/698,403 patent/US20200093899A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017016302A (es) | 2018-03-23 |
| US20180303914A1 (en) | 2018-10-25 |
| JP6858231B2 (ja) | 2021-04-14 |
| CO2018000196A2 (es) | 2018-03-28 |
| EA201890182A1 (ru) | 2018-06-29 |
| PL3318267T3 (pl) | 2021-07-12 |
| EA038110B1 (ru) | 2021-07-07 |
| EP3318267A1 (en) | 2018-05-09 |
| CA2990370C (en) | 2022-05-17 |
| KR20190141026A (ko) | 2019-12-20 |
| KR20180015256A (ko) | 2018-02-12 |
| BR112018000051A2 (pt) | 2018-09-04 |
| CA2990370A1 (en) | 2017-01-05 |
| ES2866957T3 (es) | 2021-10-20 |
| EP3318267B1 (en) | 2021-02-24 |
| MX379982B (es) | 2025-03-11 |
| EP3318267A4 (en) | 2019-02-27 |
| HK1252663A1 (zh) | 2019-05-31 |
| KR102213055B1 (ko) | 2021-02-08 |
| JP2018519326A (ja) | 2018-07-19 |
| CN107921091A (zh) | 2018-04-17 |
| US20200093899A1 (en) | 2020-03-26 |
| JP2020019775A (ja) | 2020-02-06 |
| CL2018000002A1 (es) | 2018-06-29 |
| US10561713B2 (en) | 2020-02-18 |
| KR20170004814A (ko) | 2017-01-11 |
| JP6606199B2 (ja) | 2019-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190351A1 (es) | Agente terapeutico del sindrome de hunter y metodo de tratamiento | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| CL2021002747A1 (es) | Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020) | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| EA201500923A1 (ru) | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| EA201790721A1 (ru) | Инъекционный состав бупренорфина | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| AR120399A1 (es) | Un método de tratamiento de un cáncer positivo para dll3 | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2020003697A (es) | Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas. | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| CO2020000529A2 (es) | Metodos para tratar hiperinsulinismo congenito | |
| CL2018003269A1 (es) | Ácidos carboxílicos para aplicación en la primera infancia. |